TransCode Therapeutics, Inc.
Neil Robertson is currently working as a Principal Scientist at TransCode Therapeutics, Inc. Neil previously held positions as a Postdoctoral Researcher at Michigan State University and as a Graduate Student at the University at Albany. Prior to that, Neil was a Research Assistant at the University at Buffalo. Robertson has a Ph.D. in Chemistry from the University at Albany and a B.S. in Biochemistry from the University at Buffalo. Neil has experience teaching undergraduate chemistry courses and conducting research in multiple projects.
This person is not in any teams
TransCode Therapeutics, Inc.
TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. Our lead therapeutic candidate, that we believe has blockbuster potential, targets an RNA molecule which has been shown to be the driver of metastatic disease across multiple tumor typesand has been validated pre-clinically in our lab at MGH. Our initial FIH clinical study, for which an eIND filing is planned for Q1 of 2022, is intended to provide positive proof-of-mechanism for the TTX platform.